international comparisons

Slide1: 

The top 15 pharmaceuticals in the world 2005 (Billion USD) Lipitor (Pfizer) Nexium (AstraZeneca) Seretide (GSK) Zocord (MSD) Norvasc (Pfizer) Zyprexa (Lilly) Risperdal (J&J) Ogastro/Prevacid* (Abbott) Efexor (Wyeth) Erypo/Eprex (J&J) Enbrel (Wyeth) Zoloft (Pfizer) Aranesp (Amgen) Seroquel (AstraZeneca) Plavix (BMS) Source: IMS Health

Slide2: 

The top 15 pharmaceutical companies´ sales of medicines in the world 2005 (Billion USD) Pfizer Sanofi-Aventis Novartis J&J AstraZeneca Merck & Co Roche Abbott BMS Wyeth Lilly Amgen BI Takeda GlaxoSmithKline Source: IMS Health

World pharmaceutical market, allocated on regions 2005: 

World pharmaceutical market, allocated on regions 2005 Total global market: 602 billion USD Source: IMS Health

Total pharmacy market (at ex-factory prices) average growth rate for the period 1993–2003 (%): 

Total pharmacy market (at ex-factory prices) average growth rate for the period 1993–2003 (%) Source: EFPIA member associations, PhRMA, JPMA Europe USA Japan

Slide5: 

Large mergers and acquisitions within the pharmaceutical industry since 1990 2005 2004 2003 2001 2001 2000 2000 1999 1999 1997 1996 1995 1995 1995 1994 1991 1990 Yamanouchi + Fujisawa Sanofi-Synthélabo + Aventis Pfizer + Pharmacia BASF Pharma/Knoll + Abbott Glaxo Wellcome + SmithKline Beecham Pfizer + Warner Lambert Pharmacia & Upjohn + Searle Hoechst Marion Roussel + Rhone-Poulenc Rorer Astra + Zeneca Nycomed + Amersham Ciba Geigy + Sandoz Glaxo Burroughs + Wellcome Hoechst Roussel + Marion Merrell Dow Pharmacia + Upjohn Janssen + Cilag SmithKline + Beecham Rhone-Poulenc + Rorer Astellas Pharma Sanofi-Aventis Pfizer Abbott GlaxoSmithKline Pfizer Pharmacia Aventis AstraZeneca Nycomed Amersham Novartis Glaxo Wellcome Hoechst Marion Roussel Pharmacia & Upjohn Janssen-Cilag SmithKline Beecham Rhone-Poulenc Rorer Year Companies New name Source: EFPIA

Research and development costs for a new medicine (NCE): 

Research and development costs for a new medicine (NCE) Year MUSD

The pharmaceutical industry´s R&D expenditures in Europe, USA and Japan: 

The pharmaceutical industry´s R&D expenditures in Europe, USA and Japan Year EURO Billion Europe USA Japan Source: EFPIA member associations, PhRMA, JPMA

Slide8: 

Pharmaceutical trade balance by country Ireland Switzerland France United Kingdom Sweden Denmark Germany The Netherlands Austria Belgium Norway Finland Italy Portugal Greece Spain 11 444 9 789 5 900 3 866 3 104 2 648 1 199 56 -619 -628 -648 -1 023 -1 155 -1 356 -2 658 -35 169 Country M EURO Note: All data based on SITC 54. France, Norway, Spain, Switzerland: veterinary products excluded. Grecce, Norway: provinsional. Source: EFPIA member associations (official figures)

Total number of introduced new substances (NCE´s) worldwide 1990-2004: 

Total number of introduced new substances (NCE´s) worldwide 1990-2004 Year Number of NCE´s Europe USA Japan Others Source: EFPIA

Total number of substances in active R&D 1999–2005: 

Total number of substances in active R&D 1999–2005 Number of substances Year Source: Pharmaprojects

Origin of the 23 new molecular entities (chemical and biological) launched on the world market in 2004: 

Origin of the 23 new molecular entities (chemical and biological) launched on the world market in 2004 Number Europe USA Japan Others Source: EFPIA

The price level in Sweden for the top 180 selling pharmaceuticals compared with the corresponding prices for the same products in other countries year 2004 (PPP): 

The price level in Sweden for the top 180 selling pharmaceuticals compared with the corresponding prices for the same products in other countries year 2004 (PPP) Difference (%) Germany Iceland The Netherlands Denmark Luxembourg Austria Finland Portugal France Norway Belgium Italy Spain Greece Derogation from Swedish pharmaceutical prices for certain European countries UK Switzerland Ireland Source: LFN

Slide13: 

Health care expenditures in percent of GDP in selected countries 2003 OECD Source: OECDD Health Data – 2005, October 05 Per cent

Slide14: 

Pharmaceutical expenditures in per cent of GDP in selected countries 2003 Source: OECDD Health Data – 2004, 3rd edition Per cent

Slide15: 

Pharmaceutical expenditures in percent of health care expenditures in selected countries 2003 Per cent Source: OECDD Health Data – 2005, October 05

Slide16: 

Pharmaceutical expenditures per capita in selected countries 2003 PPPs, USD Source: OECDD Health Data – 2005, October 05 Per cent